CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 14, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the discovery of a new small molecule together with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO). The new molecule has the potential to treat patients with type 2 and type 3 Gaucher disease, otherwise known as neuronopathic Gaucher disease. The discovery has been the result of the collaborative work under the existing drug discovery partnership which has been in place since 2020.
- 05/14/2024
|
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
- Fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 300 peer-reviewed publications, and 48 pharma collaborations Fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 300 peer-reviewed publications, and 48 pharma collaborations
- 05/10/2024
|
CENTOGENE Receives Nasdaq Non-Compliance Notice
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notification letter dated March 27, 2024, from the Nasdaq Stock Market LLC Listing Qualifications Department, indicating that the Company was not in compliance with the minimum bid price requirement set forth in Rule 5450(a)(1) of the Nasdaq Listing Rules since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days (from February 12 through March 26, 2024). Nasdaq Rule 5450(a)(1) requires the shares to maintain a minimum bid price of US$1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below US$1.00 for a period of 30 consecutive business days.
- 04/02/2024
|
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the extension of an ongoing partnership with Takeda (TSE: 4502/NYSE: TAK) to diagnose patients with Lysosomal Storage Disorders (LSDs).
- 03/19/2024
|
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
- Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected
- 02/29/2024
|
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
- Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company's Securities Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company's Securities
- 02/28/2024
|
CENTOGENE Explores Strategic Alternatives
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that the Company has decided to explore a range of strategic alternatives focused on sustainable long-term value creation for the benefit of its stakeholders.
- 02/28/2024
|
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
- Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development
- 01/25/2024
|
CENTOGENE Receives French Research Tax Credit Accreditation
- CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Centogene N.V.
- 01/24/2024
|
CENTOGENE Announces Preliminary Full Year 2023 Revenue
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced preliminary unaudited revenue for full year 2023 between approximately €48.5 million and €49.0 million, reflecting a growth rate over 2022 in the mid-single digits.
- 01/18/2024
|
CENTOGENE Announces Voting Results of Extraordinary General Meeting
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company's Extraordinary General Meeting. All voting items on the agenda, which included the adoption of Dutch statutory annual accounts for the financial year ended December 31, 2022, were passed by the requisite majority.
- 12/19/2023
|
CENTOGENE's Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
- CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT Study, being conducted to advance the genetic understanding of frontotemporal dementia (FTD).
- 12/13/2023
|
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has completed the transaction to form a new joint venture (JV) with Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF). The JV has been formed to increase local and regional access as well as rapid delivery of world-class genomic and multiomic testing to patients in Saudi Arabia and countries of the Gulf Cooperation Council (GCC). The new JV will be located in Riyadh, Saudi Arabia, and operate under the name ‘Lifera Omics'.
- 11/28/2023
|
CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism
- Collaborative research initiative leveraged CENTOGENE's Whole Exome Sequencing (WES) to reveal disease-causing gene called ACBD6 (Acyl-CoA Binding Domain Containing 6) Over seven years, a total of 45 affected individuals from 29 independent families in Southeast Asia, Central Asia, the Middle East, Europe, and North and South America have been identified Study guides further research for potential treatments, including genetic causes and pathways leading to Parkinson's disease CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V.
- 11/14/2023
|
CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering
- Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology
- 10/10/2023
|
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that CENTOGENE CEO Kim Stratton will present in the virtual track at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, and invites investors to participate via virtual one-on-one meetings with Ms. Stratton and CENTOGENE CFO Miguel Coego Rios.
- 09/11/2023
|
CENTOGENE Reports First Half 2023 Financial Results
- Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance
- 09/07/2023
|
Centogene shares climb after study confirms biomarker for Gaucher disease
- Shares of Centogene NV CNTG, +8.31% gained 7% premarket on Friday after the company announced data confirming the utility of its proprietary biomarker lyso-Gb1 in indicating the severity of Gaucher disease, a rare inherited disorder that affects the body's ability to break down a certain type of fat. The study results also indicate that lyso-Gb1 could help predict the clinical course of patients and personalize care for the disease, Centogene said in a release.
- 09/01/2023
|
CENTOGENE to Participate in Upcoming Conferences in August
- CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for August 2023. CENTOGENE representatives are attending events in Brazil and Switzerland, and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.
- 08/07/2023
|
Centogene shares jump on joint venture with Lifera
- Shares of Centogene NV CNTG, -2.20%, which specializes in genetic diagnostics for rare diseases, jumped 50% in premarket trading Tuesday after the company announced a joint venture with Lifera, a biopharmaceutical company owned by Saudia Arabia's Public Investment Fund. The JV brings Centogene a $30 million investment and will focus on providing multiomic testing to patients, health systems, biopharma clients and research institutions in Saudia Arabia and countries of the Gulf Cooperation Council, the company said in a release.
- 06/27/2023
|
CENTOGENE to Participate in Upcoming Conferences in May
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 05, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for May 2023. CENTOGENE representatives are attending events in Brazil, the U.S., and Germany, as well as virtually, and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.
- 05/05/2023
|
CENTOGENE to Participate in Upcoming Conferences in April
- CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for April 2023. CENTOGENE representatives will be attending events in Spain, the U.S., and Germany and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.
- 04/14/2023
|
CENTOGENE to Participate in Upcoming Conferences in March
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 08, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for March 2023. CENTOGENE representatives will be attending events in Brazil, the U.S., Saudi Arabia, Thailand, and the U.K. and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.
- 03/08/2023
|
CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its partnering conference schedule for February 2023, with a focus on rare and genetic diseases in the lead up to Rare Disease Day (RDD) on February 28th. Since 2008, RDD has been held annually on the last day of February and includes a range of activities and initiatives throughout the month. Bringing together physicians, patient organizations, researchers, medical companies, and of course, rare disease patients from around the world, RDD raises awareness and generates change for the rare disease community.
- 02/07/2023
|
CENTOGENE to Participate in Upcoming Conferences in December
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for December 2022. The Company's Pharma and CRO business development team and Diagnostics sales team will be attending events in the U.S. and Japan. CENTOGENE invites attendees to schedule one-on-one meetings.
- 12/01/2022
|
CENTOGENE to Participate in Upcoming Conferences in November
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for November 2022. The Company's Pharma and CRO business development team and Diagnostics sales team will be attending events in the U.S. and Spain. CENTOGENE invites attendees to schedule one-on-one meetings.
- 11/10/2022
|
CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced its investment and partnering conference schedule for September 2022. Company management will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York and the 9th Annual HealthTech Investment Forum (HTIF) as part of Sachs Autumn Life Sciences Week in Basel. CENTOGENE invites investors and partners to attend the presentations and schedule one-on-one meetings.
- 09/01/2022
|
CENTOGENE to Present at the H.C. Wainwright Global Investment Conference
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced that Company management will present in the virtual track at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022, and invites investors to participate via virtual one-on-one meetings.
- 05/19/2022
|
Centogene N.V. (CNTG) CEO Kim Stratton on Q4 2021 Results - Earnings Call Transcript
- Centogene N.V. (CNTG) CEO Kim Stratton on Q4 2021 Results - Earnings Call Transcript
- 03/30/2022
|
CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results for the quarter and full year ended December 31, 2021, on Wednesday, March 30, 2022, and will host a conference call and webcast to discuss these results at 2 p.m. CEST / 8 a.m. EDT that day.
- 03/23/2022
|
Centogene N.V. (CNTG) CEO Andrin Oswald on Q3 2021 Results - Earnings Call Transcript
- Centogene N.V. (CNTG) CEO Andrin Oswald on Q3 2021 Results - Earnings Call Transcript
- 11/24/2021
|
Why Centogene Shares Are Slumping After Q3 Earnings?
- Centogene N.V. (NASDAQ: CNTG) reported Q3 sales of €30.2 million, down 17% Y/Y, driven by decreasing revenues from COVID-19 testing.
- 11/24/2021
|
Earnings Preview For Centogene
- Centogene (NASDAQ:CNTG) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement.
- 11/23/2021
|
CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021
- CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results for the quarter ended September 30, 2021, on Wednesday, November 24, 2021, and will host a conference call and webcast to discuss these results at 2 p.m. CET / 8 a.m. ET that day.
- 11/18/2021
|
Centogene, Twist Join Forces For Custom Test Kits For Rare Diseases
- Centogene NV (NASDAQ: CNTG) and Twist Bioscience Corporation (NASDAQ: TWST) have signed a contract to develop and commercialize custom assay kits for rare diseases. The financial details of the deal were not disclosed.
- 10/06/2021
|
CENTOGENE's Ground-Breaking Family Genetic Research Published in the New England Journal of Medicine Reveals Path to Potential Cure for Structural Birth Defects
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced today the publication of results from a ground-breaking global genetic study in the New England Journal of Medicine (http://www.nejm.org/doi/full/10.1056/NEJMoa2033911), including findings of a potential treatment of structural birth defects caused by specific gene alterations.
- 09/29/2021
|
New Strong Sell Stocks for September 10th
- CNTG, JOAN, STRT, ZNGA, and PTVE have been added to the Zacks Rank #5 (Strong Sell) List on September 10, 2021
- 09/10/2021
|
Centogene N.V. (CNTG) CEO Andrin Oswald on Q2 2021 Results - Earnings Call Transcript
- Centogene N.V. (CNTG) CEO Andrin Oswald on Q2 2021 Results - Earnings Call Transcript
- 09/07/2021
|
Centogene N.V. (CNTG) Reports Q2 Loss, Tops Revenue Estimates
- Centogene N.V. (CNTG) delivered earnings and revenue surprises of -73.08% and 62.19%, respectively, for the quarter ended June 2021.
- 09/07/2021
|
CENTOGENE Reports Second Quarter 2021 Financial Results
- Strong Revenues and Steady Return to Core Business Growth; Surpasses Milestone of 200 Scientific Publications, Highlighting Value of Bio/Databank Strong Revenues and Steady Return to Core Business Growth; Surpasses Milestone of 200 Scientific Publications, Highlighting Value of Bio/Databank
- 09/07/2021
|
CENTOGENE to Announce Second Quarter 2021 Financial Results on September 7, 2021
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results for the quarter ended June 30, 2021, on Tuesday, September 7, 2021, and will host a conference call and webcast to discuss these results at 2 p.m. CEST / 8 a.m. EDT that day.
- 09/01/2021
|
CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the appointment of Dr. Patrice P. Denèfle as Chief Scientific Officer (CSO). Dr. Denèfle will join CENTOGENE on August 16, 2021, succeeding Phil Lambert, who has decided to leave the Company.
- 07/27/2021
|
CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the voting results of the Company's Annual General Meeting. The shareholders of the Company voted in favor of all proposals, which included the appointment of Rene Just as Chief Financial Officer and Managing Director of the company, as well as the re-appointment of Flemming Ørnskov, Hubert Birner, Holger Friedrich, Guido Alexander Prehn, Eric Souêtre, and Berndt Axel Edvard Modig to the Supervisory Board.
- 06/25/2021
|
CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years
- Highlights strategic priorities to lead data-driven insights creation for rare diseases at its Virtual Investor Event Highlights strategic priorities to lead data-driven insights creation for rare diseases at its Virtual Investor Event
- 06/22/2021
|
CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor Event
- Further signs of recovery in the core rare disease business Further signs of recovery in the core rare disease business
- 06/16/2021
|
Centogene N.V. (CNTG) Stock Jumps 7.5%: Will It Continue to Soar?
- Centogene N.V. (CNTG) saw its shares surge in the last session with trading volume being higher than average.
- 06/15/2021
|
CENTOGENE to Announce Q1 2021 Financial Results on June 16, 2021
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 09, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results for the quarter ended March 31, 2021, on Wednesday, June 16, 2021.
- 06/09/2021
|
CENTOGENE Announces Virtual Investor Event
- New leadership team to present vision, strategy, and execution roadmap New leadership team to present vision, strategy, and execution roadmap
- 06/07/2021
|
3 Medical Info System Stocks to Bank on Despite Decline in COVID-19 Cases
- The COVID-19 pandemic has in a way increased the pace of progress of Medical Information Systems industry.
- 06/04/2021
|
CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia
- Observational Study to Advance Genetic Understanding of FTD Being Conducted With Support From Alector Observational Study to Advance Genetic Understanding of FTD Being Conducted With Support From Alector
- 06/02/2021
|
CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 01, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the launch of NEW CentoXome, an enhanced next-generation sequencing-based assay.
- 06/01/2021
|
CENTOGENE Announces the Nomination of Rene Just as Chief Financial Officer
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 26, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the nomination of Rene Just as Chief Financial Officer (CFO), which will be proposed to the shareholders at the upcoming Annual General Meeting (AGM). Rene will join the Company on June 1, 2021, to work closely through the transition with current CFO Richard Stoffelen, who has decided to leave the Company as of June 30, 2021.
- 05/26/2021
|
CENTOGENE Appoints Michael Motz as Chief Commercial Officer, Pharmaceuticals
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced the appointment of Dr. Michael Motz as Chief Commercial Officer, Pharmaceuticals, who will join the company on June 1, 2021.
- 05/18/2021
|
CENTOGENE Extends Global Parkinson's Disease Study
- Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson's disease (PD)
- 05/10/2021
|
Centogene (CNTG) Enters Oversold Territory
- Centogene (CNTG) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
- 05/07/2021
|
New CentoMD® 6.0 Update Brings Deeper Insights Into Rare Diseases
- CENTOGENE's rare disease mutation database offers new features and previously unpublished variants CENTOGENE's rare disease mutation database offers new features and previously unpublished variants
- 05/06/2021
|
CENTOGENE Discovers Six New Rare Diseases by Leveraging the Strength of Its Bio/Databank
- Research leads to diagnosis and treatment options for rare disease patients Research leads to diagnosis and treatment options for rare disease patients
- 05/05/2021
|
4 Medical Products Stocks Set to Beat This Earnings Season
- Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.
- 05/04/2021
|
Centogene N.V. (CNTG) CEO Andrin Oswald on Q4 2020 Results - Earnings Call Transcript
- Centogene N.V. (CNTG) CEO Andrin Oswald on Q4 2020 Results - Earnings Call Transcript
- 04/15/2021
|
CENTOGENE Reports Record Fourth Quarter and Full Year 2020 Financial Results
- Delivers very strong financial results in unprecedented year Delivers very strong financial results in unprecedented year
- 04/15/2021
|
CENTOGENE Extends Partnership With Takeda
- CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it has extended its partnership with Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) to diagnose patients with certain genetic disorders.
- 04/14/2021
|
CENTOGENE to Announce Full Year 2020 Financial Results on April 15, 2021
- CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 08, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will issue a press release reporting its financial results for the full year ended December 31, 2020, on Thursday, April 15, 2021, and will host a conference call to discuss these results at 8 a.m. EDT that day.
- 04/08/2021
|
CENTOGENE Reaches 10,000 Participant Milestone in Global Parkinson's Disease Study
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today a significant milestone in its Rostock International Parkinson's Disease (ROPAD) Study, with the recruitment and genetic testing of 10,000 participants. Including more than 120 study sites around the world, CENTOGENE is leading the largest study of its kind – a global observational study focusing on the role of genetics in Parkinson's disease (PD).
- 03/09/2021
|
CENTOGENE Announces Voting Results of Extraordinary General Meeting
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced the voting results of the Company's Extraordinary General Meeting. The shareholders of the Company voted in favor of all proposals, which included the appointments of Dr. Andrin Oswald as Managing Director and Dr. Jonathan Sheldon as Supervisory Director, the reappointment of Mr. Richard Stoffelen as Managing Director, and adjustments to the compensation of the Supervisory Board.
- 12/18/2020
|
Centogene N.V. (CNTG) CEO Andrin Oswald on Q3 2020 Results - Earnings Call Transcript
- Seeking Alpha Transcripts | Healthcare Centogene N.V. (CNTG) CEO Andrin Oswald on Q3 2020 Results - Earnings Call Transcript Dec. 16, 2020 2:58 PM ET | | About: Centogene N.V. (CNTG) by: SA Transcripts Subscribers Only Earning Call Audio Centogene N.V. (NASDAQ:CNTG) Q3 2020 Earnings Conference Call December 16, 2020 8:30 AM ET Company Participants Sun Kim - Investor Relations Richard Stoffelen - Chief Financial Officer
- 12/16/2020
|
Recap: Centogene Q3 Earnings
- Shares of Centogene (NASDAQ:CNTG) remained unaffected in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 97.88% year over year to ($0.30), which missed the estimate of ($0.28).
- 12/16/2020
|
CENTOGENE Reports Third-Quarter 2020 Financial Results and Increases Full Year Guidance
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today provided an update on its corporate progress and reported its financial results for the three and nine months ended September 30, 2020.
- 12/16/2020
|
CENTOGENE to Report Third-Quarter 2020 Financial Results on December 16, 2020
- CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will issue a press release reporting its financial results for the three months ended September 30, 2020, on Wednesday, December 16, 2020, and will host a conference call to discuss these results at 8 a.m. EST that day.
- 12/09/2020
|
CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”)
- CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN and MUNICH, Germany, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, and Alnylam Pharmaceuticals, Inc. (“Alnylam”), the leading RNAi therapeutics company, announced today the launch of a new joint clinical screening program: the genetic screening of the at-risk population for hereditary T ransthy R etin-related AM yloidosis and longitudinal moni toring of TTR positive subjects (the “TRAMmoni TTR S tudy”).
- 12/08/2020
|
CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
- Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global No-Cost Testing Program to Additional Countries Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global No-Cost Testing Program to Additional Countries
- 11/25/2020
|
CENTOGENE Announces Nomination of Jonathan Sheldon to Supervisory Board
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced the nomination of Dr. Jonathan G. Sheldon as a member of the Supervisory Board, which will be proposed to the shareholders at an upcoming Extraordinary General Meeting (EGM). Dr. Sheldon will also serve with immediate effect as a member ad interim of the Company's Supervisory Board.
- 11/13/2020
|
Fujirebio Europe and CENTOGENE Enter Partnership to Provide Rapid and High-Quality Preventive SARS-CoV-2 Antigen Testing
- GENT, Belgium and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and Fujirebio Europe announced today to have entered a partnership to leverage LUMIPULSE® G technology for large-scale COVID-19 antigen testing with further deployment in German airports.
- 11/09/2020
|
CENTOGENE Opens Walk-In COVID-19 Testing Facility at Berlin Brandenburg Airport
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today the opening of its walk-in COVID-19 testing facility at the newly opened Berlin Brandenburg Airport (BER).
- 11/05/2020
|
CENTOGENE and Evotec Expand Collaboration Into Gaucher Disease
- CAMBRIDGE, Mass. and ROSTOCK, Germany and HAMBURG, Germany and BERLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809), a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches, today announced that the two companies have expanded their existing drug discovery partnership related to Gaucher disease – a genetic lysosomal storage disorder caused by mutations in the glucocerebrosidase gene. The parties intend to develop a treatment for Gaucher patients. Prof. Arndt Rolfs, CEO of CENTOGENE, said, “Our collaboration with Evotec further underlines CENTOGENE’s commitment to driving biomarker discoveries and accelerating orphan drug development by leveraging our global expertise in rare hereditary diseases. In particular, we are able to draw on over 20 years of knowledge and research of Gaucher disease. By continuing our work alongside Evotec, we will accelerate transformational medical solutions in the rare disease field.”Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “The partnership with CENTOGENE supports and complements our patient-centric drug discovery approach in Gaucher disease. We highly value CENTOGENE’s biomarker expertise and real-world data-based global proprietary rare disease platform, which fits perfectly to our iPSC-based drug discovery platform. The combination should help identify disease-modifying treatments for this underserved patient population.”Dr. Philip Lambert, Chief Scientific Officer at CENTOGENE, added, “The potential to further the understanding of rare diseases connected to mutations in the GBA gene is extremely important to patients and their families around the world, and we hope that today’s collaboration agreement will help lead to transformational personalized treatments for these patients.”Under the terms of the expanded agreement, CENTOGENE and Evotec will work together to research, discover, and develop medical solutions for rare diseases related to the protein target glucocerebrosidase (“GBA”), a well-known gene linked to Gaucher disease. The collaboration brings together Evotec’s leading induced pluripotent stem cell (“iPSC”) platform and broad drug discovery and development capabilities with CENTOGENE’s global proprietary rare disease platform, including insights as well as iPSC lines. Ultimately, the aim is to address the needs of this orphan drug indication. The collaboration builds on the partnership Evotec and CENTOGENE entered in 2018 with the goal to discover and develop novel small molecules in rare hereditary metabolic diseases.About Evotec SEEvotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,300 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women’s health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec. About CENTOGENECENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 3.0 billion weighted data points from over 530,000 patients representing over 120 different countries as of March 31, 2020. The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of March 31, 2020, the Company collaborated with 39 pharmaceutical partners covering over 45 different rare diseases. Important Notice and Disclaimer This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2019 on Form 20-F filed with the SEC on April 23, 2020 and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov. CONTACT: CENTOGENE Ben Legg Corporate Communications press@centogene.com Evotec Gabriele Hansen SVP Global Communications & Marketing +49.(0)40.560 81-255 gabriele.hansen@evotec.com FTI Consulting Bridie Lawlor +1.917.929.5684 bridie.lawlor@fticonsulting.com
- 08/20/2020
|
CENTOGENE Opens Walk-In COVID-19 Testing Facility at Hamburg Airport
- CENTOGENE’s CentoTruck A mobile testing solution for COVID-19 CENTOGENE COVID-19 Testing Facility at Hamburg Airport, Germany CENTOGENE staff ready for passengers at walk-in COVID-19 test facility at Hamburg Airport CENTOGENE COVID-19 Testing Facility at Hamburg Airport, Germany CENTOGENE staff ready for passengers at walk-in COVID-19 test facility at Hamburg Airport CENTOGENE COVID-19 Testing Facility at Hamburg Airport, Germany CENTOGENE staff ready for passengers at walk-in COVID-19 test facility at Hamburg Airport * CENTOGENE expands its SARS-CoV-2 testing solution to Hamburg Airport after successfully launching the first walk-in COVID-19 test facility at Frankfurt Airport in June 2020 in cooperation with Lufthansa * Company’s PCR tests now available for passengers departing from Hamburg, and returning to Hamburg from non-risk countries only, as well as the general public * Expansion of testing to Hamburg Airport further paves the way towards a new normal for our societies and economiesCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today the opening of its new walk-in COVID-19 test facility at Hamburg Airport.CENTOGENE is now offering coronavirus testing at Hamburg airport for all individuals who need to perform a COVID-19 test, including returning travelers from non-risk countries. Passengers can now be conveniently tested daily from 6:00 a.m. to 8:00 p.m. CEST directly at the test center located at Terminal 1. The Hamburg walk-in COVID-19 test facility is also open to the general public. For more information, visit https://www.centogene.com/covid-19/test-centers/hamburg-airport.html“Traveling is essential for both, our economy and society,” said Dr. Volkmar Weckesser, CENTOGENE’s Chief Information Officer. “By working together with Hamburg Airport, we have proven our blueprint works to continue facilitating widespread testing – enabling safe international travel and preventing a further outbreak of the novel Coronavirus.”“We very much welcome that our passengers now have the opportunity to have themselves tested directly in Hamburg. In these special times, it is particularly important that travel is safe and yet comfortable,” said Dr. Björn Becker, Senior Director Product Management Ground & Digital Services Lufthansa Group.Dedicated to the Highest Quality Testing to Restore Air TravelCENTOGENE is dedicated to providing quality testing to prevent a further outbreak and restore air travel. The test detects an infection of SARS-CoV-2 by detecting specific RNA molecules that originate from the genome of the disease-causing coronavirus. The diagnostic procedure includes: RNA extraction, transcription of the RNA into complementary DNA (cDNA) by means of reverse transcription, and amplification (multiplication) of virus-specific cDNA by means of polymerase chain reaction (PCR). The presence of cDNA in the amplification product shows that virus particles were in the sample, and thus indicates an active infection with SARS-CoV-2.The method used is based on the published method by Prof. Drosten (Charité, Berlin). This test is referred to in the WHO documents as the “WHO Charité” test. The analytical steps and in particular the target sequences used to detect the viral RNA by RT-PCR correspond exactly to the publication by Corman, Bleicker, Brünink, Drosten, Landt, Koopmans, Zambon from January 17, 2020, and were validated in interlaboratory tests, as well as in cooperation with the laboratory by Prof. Drosten. The test has also been validated in CENTOGENE's CAP / CLIA / ISO certified analytical laboratory and has received Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) for use by authorized laboratories.As part of the comprehensive test solution, individuals can register for testing using a secure SARS-CoV-2 Test Portal – following stringent data privacy measures, while delivering time-sensitive diagnostics. CENTOGENE acts in compliance with the current specifications of GDPR (German Data Protection Regulation ‘Datenschutzgrundverordnung’) and Health Insurance Portability and Accountability Act (HIPAA).About CENTOGENECENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 3.0 billion weighted data points from over 530,000 patients representing over 120 different countries as of March 31, 2020.The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of March 31, 2020, the Company collaborated with 39 pharmaceutical partners covering over 45 different rare diseases.Important Notice and Disclaimer This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2019 on Form 20-F filed with the SEC on April 23, 2020 and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov. Photos accompanying this announcement are available at:https://www.globenewswire.com/NewsRoom/AttachmentNg/40b0db1f-9414-4443-8a9b-1b99d149f3achttps://www.globenewswire.com/NewsRoom/AttachmentNg/99a9e557-181a-460a-91e6-0443603ba57ahttps://www.globenewswire.com/NewsRoom/AttachmentNg/3c232192-cd7e-45f1-9f72-277a77dd7c09https://www.globenewswire.com/NewsRoom/AttachmentNg/2cdc4f60-ca2f-45ec-b815-453e4861bd9c CONTACT: Media Contact: CENTOGENE Ben Legg Corporate Communications press@centogene.com FTI Consulting Bridie Lawlor +1.917.929.5684 bridie.lawlor@fticonsulting.com
- 08/19/2020
|
CentoMD® Update Reveals Further Insights Into Rare Diseases
- CAMBRIDGE, Mass., and ROSTOCK and BERLIN, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today a release of CentoMD® 5.8 ̶ the latest update of the Company’s curated mutation database for rare diseases including epidemiologic, phenotypic, and clinical data. Since December 2019, the number of analyzed cases in CentoMD® has grown to more than 430,000, and the number of total unique variants increased to over 12.7 million, covering more than 120 countries. This latest update underlines the company’s continuous commitment to unlocking the deepest knowledge in rare diseases, such as disease-causing variants, precise genetic and biomarker information, and allele frequency. CentoMD® 5.8 includes: * More than 12.7 million unique variants * More than 81,000 classified and curated variants * More than 199,000 individuals linked to HPO termsProf. Arndt Rolfs, CENTOGENE Chief Executive Officer, said, “CentoMD®, what we believe to be the world’s largest curated mutation database for rare diseases, plays an invaluable role in facilitating the most comprehensive diagnosis for rare disease patients. With the latest and most accurate information, we are able to continue bridging the gap between genetic variants and clinical interpretation – ultimately ending patients’ diagnostic odysseys and accelerating the development of life-saving treatments.”Dr. Volkmar Weckesser, CENTOGENE Chief Information Officer, added, “We continuously strive to provide the most detailed, evidence-based genetic, proteomic, and metabolic information. With each update, we are able to unlock further insights into rare diseases – providing solutions for patients, physicians, and pharma partners around the world.”The Company has also recently released an update of CentoLSD™, which is believed to be the world's largest knowledge-driven lysosomal storage disease ("LSD") database, to enhance the global understanding and potential treatment opportunities for rare disease patients. Powered by CentoMD®, CentoLSD™ allows for researchers, pharmaceutical partners, and clinicians to access a comprehensive database of GBA and GLA genetic variants classified through a standardized curation workflow.About CENTOGENECENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 3.0 billion weighted data points from over 530,000 patients representing over 120 different countries as of March 31, 2020.The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of March 31, 2020, the Company collaborated with 39 pharmaceutical partners covering over 45 different rare diseases. CONTACT: Media Contact: CENTOGENE Melissa Hall Corporate Communications press@centogene.com FTI Consulting Bridie Lawlor +1.917.929.5684 bridie.lawlor@fticonsulting.com
- 08/11/2020
|
CENTOGENE Supports Tajikistan in Fight Against the COVID-19 Pandemic
- * CENTOGENE expands ongoing development cooperation with Ministry of Health and Social Protection of the Population of Tajikistan (MoH) to now include COVID-19 testing * The project supports access to testing materials and laboratory devices for SARS-CoV-2 testing – funded by the German Federal Ministry for Economic Cooperation and Development (BMZ) and technical expertise, organizational support, and training provided by CENTOGENECAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it has expanded its ongoing development cooperation with the Ministry of Health and Social Protection of the Population of Tajikistan to now include SARS-CoV-2 testing. The project will enable Tajikistan to increase their testing capacities – helping the country to identify and quarantine patients with a SARS-CoV-2 infection and hence, control infection chains to minimize the outbreak of COVID-19. In the framework of this not-for-profit project, the National Reference Laboratory (NRL) in Dushanbe has received reagents, laboratory devices, swabs, and transport systems for qPCR testing. CENTOGENE will train the Tajik experts to conduct SARS-CoV-2 testing using Standard Operating Procedures (SOPs) and training tools in development by CENTOGENE scientists, with follow-up audiovisual consultations to address future questions and quality management related challenges.“Building on our valuable experiences within the ongoing cooperation with CENTOGENE, we highly welcome this initiative to enhance COVID-19 diagnosis for patients in Tajikistan,” said Dr. Gafur Muhsinzoda, First Deputy Minister of Health in Tajikistan.Prior to this initiative, CENTOGENE signed a memorandum of understanding with the Ministry of Health in July 2019 to cooperate in the field of rare diseases. The project consists of three cornerstones: training of Tajik doctors, pro bono diagnostic of patients and support to affected families with information, and access to patient networks. It is jointly funded by CENTOGENE and the develoPPP.de program of the German Federal Ministry for Economic Cooperation and Development (Bundesministerium für Wirtschaftliche Zusammenarbeit und Entwicklung (BMZ)).Prof. Arndt Rolfs, CEO of CENTOGENE, stated, “This co-funding partnership represents an innovative way to work in close cooperation with the public sector – supporting countries with much needed help for pressing healthcare challenges. In the midst of recent obstacles, it is important to continue working together to increase testing efforts and diagnose patients at the earliest possible point.”About CENTOGENECENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 3.0 billion weighted data points from over 530,000 patients representing over 120 different countries as of March 31, 2020.The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of March 31, 2020, the Company collaborated with 39 pharmaceutical partners covering over 45 different rare diseases.Important Notice and Disclaimer This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2019 on Form 20-F filed with the SEC on April 23, 2020 and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may obtain these documents by visiting EDGAR on the SEC website at www.sec.gov. CONTACT: Media Contact: CENTOGENE Melissa Hall Corporate Communications press@centogene.com FTI Consulting Bridie Lawlor +1.917.929.5684 bridie.lawlor@fticonsulting.com
- 08/04/2020
|
CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs
- * The combination of real-life data sets in rare diseases with innovative big data/artificial intelligence/novel scientific computational knowledge will transform biomedical research, product development, and therapy. * Real-life data and Innovative Bioinformatic Algorithms (RIBA project) will enable the creation of a powerful environment to accelerate, de-risk, and improve the development of new orphan drugs for many diseases and disease areas. * RIBA develops and offers data-/computing-driven solutions to guide the highest and most precise innovation for a new way of drug development in a modern biopharmaceutical environment. * The collaboration will start with Epilepsy as the first indicationCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and HEIDELBERG, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and Molecular Health, a leading company in the field of data and computing science for precision medicine, announced today that they will collaborate exclusively to initiate the Real-life data and Innovative Bioinformatic Algorithms (RIBA) project – starting with Epilepsy as the first indication. RIBA aims to foster a unique novel precision medicine environment to accelerate, de-risk, and improve the development of new orphan drugs based on the combination of large real-life data sets in rare disease with innovative big data, innovative artificial intelligence, as well as computational algorithms and expertise. Both companies are convinced that this strategy of merging real-life data with a global curated biomedical knowledge, as well as applying artificial intelligence and scientific computing will radically change and transform biomedical research, product development, and therapy. Additionally, it will offer data-/computing-driven solutions to guide the highest and most precise innovation for the new way of drug development in a modern biopharmaceutical environment.Prof. Arndt Rolfs, CENTOGENE Chief Executive Officer, stated, “We are excited about this collaboration. Both companies have been analyzing the potential interaction for an extended period of time and are deeply convinced that now is the right time to start an exclusive cooperation focusing on rare genetic diseases. The complementary expertise and knowledge of both companies will allow us to reduce the time to develop a new orphan drug by combining of real-life data and innovative computational biomedical expertise. CentoMD®, one of the world’s largest rare disease data repositories, allows us to take advantage of the high quality of the real-life data from a global cohort of more than 500,000 consented patients. The extraordinary expertise of Molecular Health will not only speed up the identification of new targets in rare disease, but also allow us to de-risk and accelerate the development of new orphan drugs.”“By starting this exciting collaboration between our companies, we are initiating and building a unique novel model of personalized healthcare. The combination of both companies’ data and expertise will ultimately transform modern drug development and therapy. It will allow for the development of better drugs with higher specificity and safety, lower attrition rates in clinical studies, and a faster time to market to help patients with severe diseases worldwide through novel therapies,” said Dr. Friedrich von Bohlen, Molecular Health Chief Executive Officer. “Together with CENTOGENE, Molecular Health´s deep scientific, medical, and computational expertise will lay the fundament for personalized healthcare options in rare diseases to fulfill the promise of precision medicine.” The companies have agreed to start with Epilepsy as the first indication. Financial details were not disclosed. About CENTOGENECENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 3.0 billion weighted data points from over 530,000 patients representing over 120 different countries as of March 31, 2020.The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of March 31, 2020, the Company collaborated with 39 pharmaceutical partners covering over 45 different rare diseases.About Molecular HealthMolecular Health is a data science-focused artificial intelligence computing company enabling and improving decision making in precision medicine for healthcare organizations. The company offerings are based on the capture, curation, integration, and analysis of large biomedical and drug data sets and combining them with novel artificial intelligence and machine learning (AI/ML) technologies.For more than a decade, the company has been developing Dataome, a unique high-quality curated, interoperable system that combines clinico-molecular and drug data with proprietary analytical processes. Dataome – stand alone or in combination with customer data – enables the unlocking of actionable intelligence at the molecular level to a) improve diagnosis and therapy decisions by physicians and patients; b) enrich and support better drug discovery, drug development, trial optimization, drug differentiation and positioning for pharma and healthcare organizations; and c) more accurately predict the likelihood of success and likelihood of approval of drug candidates in clinical development for better trial prioritization and resource and investment allocation. For more information, visit www.molecularhealth.com.Important Notice and Disclaimer This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2019 on Form 20-F filed with the SEC on April 23, 2020 and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov. CONTACT: Media Contact: CENTOGENE Melissa Hall Corporate Communications press@centogene.com Molecular Health GmbH Thomas König Head of Communications & PR media@molecularhealth.com FTI Consulting Bridie Lawlor +1.917.929.5684 bridie.lawlor@fticonsulting.com
- 07/27/2020
|
CENTOGENE Announces Convenient At-Home Coronavirus Test Solution Now Available in Germany on Online Marketplace
- * CENTOGENE announces test kits for the detection of SARS-CoV-2 virus RNA now available on Amazon in Germany ─ the first of its type offered on the online marketplace * Offering includes delivery of a full, safe, and high-quality COVID-19 testing solution ─ significantly broadening access to the Company’s innovative tests * Short process times and digital transmission of reports deliver results directly to the customer * Tests validated on the basis of the World Health Organization’s (WHO)/Charité’s reference guidelinesCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 23, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that its validated COVID-19 test kit, called CentoKit-19™, is now available in Germany on Amazon.de. CENTOGENE is the first provider worldwide to make its innovative and comprehensive testing solution for the detection of SARS-CoV-2 virus RNA available to all individuals in Germany via the online marketplace.“Preventive, widespread testing represents a further, vital, and complementary individual measure when it comes to detecting and breaking infection chains at the earliest possible point. In combination with the already established measures, an end-to-end COVID-19 testing solution will support all of us as we return to the new normal – allowing us to reopen schools, attend concerts, or simply visit our families,” said Prof. Arndt Rolfs, founder and CEO of CENTOGENE. “By delivering a comprehensive offering, including detailed, easy-to-follow instructions, we are able to support our local and global community with a high quality, affordable, and accessible solution for everyone – delivered directly to their doorstep.”About CentoKit-19™The CentoKit-19™ consists of a CE-labelled CentoSwab™ (two-component dry plastic swab for oropharyngeal swab sampling), collection tube with barcode sticker, labelled and prepaid return boxes, UN3373 plastic bag, and a package insert. More information on the testing process, including the simplified and convenient workflow, can be found at www.centogene.com/corona.The CentoKit-19™ is available in Germany on both Amazon.de and AmazonBusiness.de. For Amazon customers, a single test kit as described above is available, and a family kit, which includes four complete kits, can also be purchased. For Amazon Business customers, as well as Amazon customers, test kits containing either 25 single kits or 50 units of the CentoSwab™ are available.Dedicated to the Highest Quality Testing and Data SecurityCENTOGENE is dedicated to providing quality testing to the global community. The test detects an infection of SARS-CoV-2 by detecting specific RNA molecules that originate from the genome of the disease-causing coronavirus. The diagnostic procedure includes: RNA extraction, transcription of the RNA into complementary DNA (cDNA) by means of reverse transcription, and amplification (multiplication) of virus-specific cDNA by means of polymerase chain reaction (PCR). The presence of cDNA in the amplification product shows that virus particles were in the sample, and thus indicates an active infection with SARS-CoV-2.The method used is based on the published method by Prof. Drosten (Charité, Berlin). This test is referred to in the WHO documents as the “WHO Charité” test. The analytical steps and in particular the target sequences used to detect the viral RNA by RT-PCR correspond exactly to the publication by Corman, Bleicker, Brünink, Drosten, Landt, Koopmans, Zambon from January 17, 2020, and were validated in interlaboratory tests, as well as in cooperation with the laboratory by Prof. Drosten. The test has also been validated in CENTOGENE's CAP / CLIA / ISO certified analytical laboratory and has received Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) for use by authorized laboratories.In addition to the kit and the high-throughput diagnostic procedure, the comprehensive test solution offers a secure SARS-CoV-2 Test Registration Portal – maintaining stringent data privacy measures, while delivering time-sensitive diagnostics. CENTOGENE acts in compliance with the current specifications of GDPR (German Data Protection Regulation ‘Datenschutzgrundverordnung’) and Health Insurance Portability and Accountability Act (HIPAA).About CENTOGENECENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 3.0 billion weighted data points from over 530,000 patients representing over 120 different countries as of March 31, 2020.The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of March 31, 2020, the Company collaborated with 39 pharmaceutical partners covering over 45 different rare diseases.Important Notice and Disclaimer This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2019 on Form 20-F filed with the SEC on April 23, 2020 and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov. CONTACT: Media Contact: CENTOGENE Ben Legg Corporate Communications press@centogene.com MC Services AG Anne Hennecke / Susanne Kutter 0211 529252 22 / 0211 529252 27 centogene@mc-services.eu FTI Consulting Bridie Lawlor +1.917.929.5684 bridie.lawlor@fticonsulting.com
- 07/23/2020
|
CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 -- Centogene N.V. (Nasdaq: CNTG) (“Centogene” or the “Company”), a commercial-stage company focused on rare.
- 07/09/2020
|
CENTOGENE Announces the Scientific Publication of a holistic solution in the preventive testing of COVID-19
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, today announced.
- 07/09/2020
|
CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares
- Centogene N.V. (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it and certain selling shareholders have commenced an underwritten public offering of 3,500,000 common shares of the Company, consisting of 2,000,000 common shares offered by the Company and 1,500,000 common shares offered by the selling shareholders. In addition, the selling shareholders expect to grant the underwriters a 30-day option to purchase up to an additional 525,000 common shares at the public offering price, less underwriting discounts and commissions.
- 07/07/2020
|
CENTOGENE Announces Partnership with OESIS Network for COVID-19 PCR Testing for US School Populations
- Centogene N.V. (CNTG), a commercial-stage diagnostics and genetic research company, and the OESIS Network Inc, an innovation network of more than 600 schools across the U.S., today announced a partnership for COVID-19 screening of schools. The partnership will offer RT-PCR testing that can aid schools in their return to campus in the fall and continued screening to prevent a resurgence of COVID-19 over the course of the academic school year. Given the precious resources of schools public and private, the test will be offered at an affordable price and less than the COVID-19 clinical diagnostic reimbursement price announced in April for Medicare Part B for high throughput, technician intensive, and time intensive tests.
- 07/06/2020
|
CENTOGENE Receives FDA Emergency Use Authorization for COVID-19 Molecular Diagnostic Test
- Centogene N.V. (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the company's SARS-CoV-2 RT-PCR test. “CENTOGENE is proud to have received this accelerated authorization from the FDA, which recognizes our continued commitment to the highest quality standards amid this global pandemic,” said Ellen Karges, SVP Regulatory Compliance & Quality Management.
- 07/02/2020
|
Centogene (CNTG) Surges: Stock Moves 8.4% Higher
- Centogene (CNTG) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
- 07/01/2020
|
Air Travel Is Returning to the U.S. That’s Great News for Southwest Airlines Stock.
- (LUV) shares are soaring 7.5% after a double upgrade from (GS) amid hopes that testing could help travelers feel safer at airports even as record numbers of new coronavirus infections limit travel. Analyst Catherine O’Brien boosted her rating on Southwest (LUV) to Buy from Sell.
- 06/29/2020
|
CENTOGENE, Lufthansa, and Fraport Launch the First Walk-In COVID-19 Testing Facility in Germany at Frankfurt Airport
- CENTOGENE (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it has partnered exclusively with Lufthansa and with Fraport, the operator of Frankfurt Airport, to offer COVID-19 testing to passengers flying to and from Frankfurt Airport (FRA). Serving as a blueprint to opening international borders, this first walk-in testing solution in Germany will aid with regulations when entering countries.
- 06/29/2020
|
Lufthansa to link Covid-19 tests with tickets in effort to avoid quarantine
- Lufthansa is to offer passengers Covid-19 tests at Frankfurt airport that provide results within hours and can be linked to individual tickets in an effort to allow travellers to avoid quarantine. The airline has joined forces with German company Centogene, which opened a walk-in testing centre at the airport on Monday that it said would act as a “blueprint to opening international borders”. Passengers coming through the hub will be able to pay for a test that provides a result within two to three hours, and that will soon be integrated with Lufthansa boarding passes.
- 06/29/2020
|
CENTOGENE Announces Change in Supervisory Board
- Centogene N.V. (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that its Supervisory Board member Christoph Ehlers has resigned from office, effective June 15, 2020. After serving more than six years as member of the Company’s Supervisory Board, Mr. Ehlers has decided to step down due to personal circumstances. “We are extremely grateful to Christoph for his contributions to CENTOGENE as both a member of the Supervisory Board and one of our initial stakeholders,” states Prof. Arndt Rolfs, CEO of CENTOGENE.
- 06/23/2020
|
CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 15, 2020 -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world.
- 06/15/2020
|
Centogene NV to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / June 15, 2020 / Centogene NV (NASDAQ:CNTG) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on June 15, 2020 at 8:00 AM Eastern ...
- 06/15/2020
|
CENTOGENE to Report First-Quarter 2020 Financial Results on June 15, 2020
- Centogene N.V. (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will issue a press release reporting its financial results for the three months ended March 31, 2020 on Monday, June 15, 2020, and will host a conference call to discuss these results at 8 a.m. EST that day. CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies.
- 06/08/2020
|
German manufacturer uses weekly Covid-19 tests to stay open
- Located near a sewage plant on the outskirts of Frankfurt, engineering company Holzhauer-Pumpen appears an unlikely pioneer. “There are no exceptions, not even for our cleaning staff,” managing director Christian Trahan explains from his office at Holzhauer’s headquarters in Karben, a small town just outside of Frankfurt.
- 06/05/2020
|
CENTOGENE Announces Changes in Senior Management Team
- Centogene N.V (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that Mr. Oved Amitay will be stepping down as Chief Business Officer (“CBO”) and leaving the Company effective May 31, 2020. Mr. Amitay will continue his work for rare diseases patients in the non-profit sector, where he will serve as Chief Executive Officer of a patient advocacy organization.
- 05/15/2020
|
CENTOGENE Announces Statewide COVID-19 Testing for Nursing Homes in Mecklenburg-Western Pomerania, Germany
- Centogene N.V. (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced it will be offering COVID-19 testing for nursing homes in the state of Mecklenburg-Western Pomerania, Germany - the location of the Company’s headquarters. By providing tests to nursing homes, we aim to protect the vulnerable nursing home population and diagnose them at the earliest possible point.
- 05/12/2020
|
Blueprint for Germany: CENTOGENE Provides Coronavirus Testing for German High School
- CENTOGENE (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it will be providing its fully validated SARS-CoV-2-PCR tests to students from the Carolinum High School, the largest high school in Neustrelitz, Germany. In doing so, the Company hopes to spearhead a return to normalcy for students ─ creating a blueprint for other schools throughout Germany.
- 05/08/2020
|
CENTOGENE Expands Senior Leadership Team with Newly Appointed Senior Vice President Communication and Marketing
- CENTOGENE (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced the expansion of its Senior Leadership Team with the appointment of Angelos Baxevanis as Senior Vice President Communication and Marketing. With nearly two decades of experience in the field, Angelos will have the overall responsibility of further developing the marketing and communication strategies, establishing internal marketing workflows, and further positioning CENTOGENE as a leading provider of medical solutions for rare disease patients. Angelos joins CENTOGENE from AAB Consulting Inc. where he was working with Sobi Pharmaceuticals in various projects on enhancing commercial capabilities in the rare disease area.
- 05/06/2020
|
CENTOGENE Announces Global Expansion of COVID-19 Testing
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN,, May 05, 2020 -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world.
- 05/05/2020
|
Veracyte (NASDAQ:VCYT) versus Centogene (NASDAQ:CNTG) Financial Comparison
- Veracyte (NASDAQ:VCYT) and Centogene (NASDAQ:CNTG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends. Analyst Ratings This is a breakdown of recent ratings and price targets for Veracyte and Centogene, as […]
- 04/27/2020
|
Citi cuts view on Illumina in premarket analyst action
- Bausch Health Companies (NYSE:BHC) initiated with Buy rating and $30 (84% upside) price target at Citigroup. Shares up 1% premarket.Radius Health (NASDAQ:RDUS) initiated with Hold rating and $20 (16%
- 04/24/2020
|
The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks htitting 52-week highs April 22.) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Johnson & Johnson (NYSE: JNJ) (reacted to a sell-side upgrade) * Cue Biopharma Inc (NASDAQ: CUE)
- 04/23/2020
|
Centogene Reports Financial Results For Full Year 2019 and Highlights Recent Progress
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 23, 2020 -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms.
- 04/23/2020
|
Centogene Reports Financial Results For Full Year 2019 and Highlights Recent Progress
- CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on...
- 04/23/2020
|
Centogene NV to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / April 23, 2020 / Centogene NV (NASDAQ:CNTG) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on April 23, 2020 at 8:00 AM Eastern ...
- 04/23/2020
|
CENTOGENE Releases a New Swab Product to Facilitate the Simple Diagnosis of COVID-19
- CENTOGENE (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced the production and global distribution of CentoSwab™. Manufactured in Germany, the kit consists of a sterile package containing a swab and collection tube. This solution is part of the Company’s global initiative to support the logistics and fast diagnosis of COVID-19 as early as possible.
- 04/21/2020
|
The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision
- Biotech stocks staged a nice recovery along with the broader markets in the week ended April 17.Apart from the broader market sentiment, big moves in biopharma companies such as Johnson & Johnson (NYSE: JNJ) and Gilead Sciences, Inc. (NASDAQ: GILD) also supported sentiment. The former reported strongly
- 04/19/2020
|
CENTOGENE and Ubirch Create Secure Blockchain Solution for the Successful Fight Against COVID-19
- CENTOGENE (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and the Cologne-based blockchain start-up Ubirch today announced a joint solution for the successful fight against the effects of SARS-CoV-2 ─ the virus causing COVID-19 ─ on the economy and social life in Germany. In the future, SARS-CoV-2 test results will be stored on the blockchain and can be retrieved at any time ─ serving as a virtual certificate of immunity to the virus. The current contact restrictions in Germany cannot be upheld until a Coronavirus vaccine is ready for market, which has major consequences on the economy and the ability for individuals to move about freely.
- 04/17/2020
|
CENTOGENE to Report Full Year 2019 Financial Results on April 23, 2020
- CENTOGENE (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will report financial results for the year ended December 31, 2019, on Thursday, April 23, 2020, and will host a conference call on the same day at 8 a.m. Eastern Time. CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 2.1 billion weighted data points from approximately 500,000 patients representing over 120 different countries as of December 31, 2019, or an average of approximately 600 data points per patient.
- 04/16/2020
|
CENTOGENE Announces Opening of Laboratory in Hamburg, Germany
- CENTOGENE (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will open a new laboratory in Hamburg, Germany ─ acquiring the former laboratory facilities and equipment of Provecs Medical GmbH, a company formerly active in cancer immunotherapy. The new laboratory, which is opening in April 2020, will enable increased testing capacity for the COVID-19 virus and will also result in the expansion of laboratory capacity for the Company’s diagnostic testing of rare genetic diseases.
- 04/15/2020
|
Centogene (NASDAQ:CNTG) vs. Guardant Health (NASDAQ:GH) Financial Analysis
- Centogene (NASDAQ:CNTG) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk. Analyst Recommendations This is a breakdown of recent ratings and price targets for Centogene and Guardant Health, […]
- 04/02/2020
|
Analyzing Laboratory Corp. of America (NYSE:LH) and Centogene (NYSE:CNTG)
- Laboratory Corp. of America (NYSE:LH) and Centogene (NASDAQ:CNTG) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation. Analyst Recommendations This is a breakdown of current recommendations and price targets for Laboratory Corp. […]
- 03/25/2020
|
Coronavirus Scare Supports These Biotech ETFs & Stocks
- Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.
- 03/24/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (NASDAQ: CNTG) * Gilead Sciences, Inc. (NASDAQ: GILD) * Imara Inc (NASDAQ: IMRA) * Regeneron Pharmaceuticals
- 03/20/2020
|
CENTOGENE Announces Commencement of Testing for COVID-19
- CENTOGENE (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced that it will commence testing for the novel coronavirus, or COVID-19. Testing for the virus is part of the Company’s initiative to help local, national and international authorities in their efforts to diagnose cases of COVID-19. Initially, the Company will provide testing for the Mecklenburg-Western Pomerania region and the Company expects to expand testing activities to additional geographical areas within the upcoming weeks.
- 03/18/2020
|
CENTOGENE Announces Changes in Supervisory Board
- CENTOGENE N.V. (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced changes to its Supervisory Board. Mr. Jacob Kaluski, a member of the Supervisory Board since 2014, has decided to resign from his office with effect from March 16, 2020. The Supervisory Board would like to thank Mr. Kaluski for his valuable contributions to CENTOGENE’s success over the past six years, during which CENTOGENE has developed into a leading contributor in the battle against rare diseases.
- 03/17/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
CENTOGENE Announces Departure of Dirk Ehlers From Executive Board
- CENTOGENE (CNTG) ─ The Company today announced that Dr. Dirk H. Ehlers, COO and President of its Clinical Diagnostics Division, has decided to step down from his role after the Annual General Meeting in June 2020 and leave the Company for personal reasons. Prof. Dr. Arndt Rolfs, CEO of the Company, stated, “We want to thank Dirk for his significant contributions to CENTOGENE and wish him well.”
- 03/09/2020
|
The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5.) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Centogene NV
- 03/06/2020
|
CENTOGENE Marks Rare Disease Day 2020 With a Global Line up of Events
- CENTOGENE (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, will be raising awareness and building community for all those affected by rare genetic diseases with simultaneous events in Berlin, Germany, Lahore, Pakistan, and Mexico City, Mexico on Rare Disease Day 2020. CENTOGENE’s Rare Disease Day events will bring together patients, advocacy groups, policy makers, researchers, health professionals, and the wider community – focused on improving the overall knowledge and identifying solutions to the challenges that rare diseases pose to patients and their families.
- 02/29/2020
|
CENTOGENE Expands Senior Leadership Team with Newly Appointed Chief Data Officer
- CAMBRIDGE, Mass. and ROSTOCK, Germany, Feb. 25, 2020 -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and.
- 02/25/2020
|
CENTOGENE Biobank Receives Accreditation from College of American Pathologists
- State-of-the-art Biorepository in Rostock, Germany is the first CAP-accredited repository outside the U.S. CAMBRIDGE, Mass. and ROSTOCK, Germany, Feb. 12, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced that its biorepository in Rostock, Germany, which they believe holds the largest diversity of positive tested cases in the field of inherited rare diseases, has received accreditation from the College of American Pathologists (CAP). The CAP’s Biorepository Accreditation Program is designed to improve the quality and consistency of biorepositories through requirements for standardization that will result in high-quality human specimens and genetic materials that can be used to support research.
- 02/12/2020
|
CentoMD® Update Reveals Continued Growth of Rare Hereditary Disease Knowledge Base
- In an update released today by CENTOGENE (CNTG) to CentoMD® - the Company’s data repository of epidemiologic, phenotypic, and clinical data, - since September 2019 the number of analyzed cases has grown by 11% to more than 400,000, and the number of total variants has increased to 12.2 million from across 120 countries. This latest update demonstrates furthers connections between genetic variants and clinical interpretation, by combining precise clinical genetic and biomarker information. Newly generated knowledge and data are based on disease-causing variants confirmed by biomarker data.
- 12/16/2019
|
